Analysis of the efficacy of Bestifan (Viliru) in the treatment of renal cancer and actual patient feedback

Belzutifan (Belzutifan, trade name: Welireg) is a targeted drug mainly used to treat advanced or metastatic clearing cell type renal cells. cell carcinoma (ccRCC), especially renal cancer associated with von Hippel-Lindau syndrome (VHL). The drug exerts anti-tumor effects by inhibiting hypoxia-inducible factor 2α (HIF-2α). Since being approved by the FDA in 2021, bezutivan has shown good clinical efficacy and tolerability, especially in refractory patients.

1. Efficacy analysis

Bestivan has shown significant anti-tumor activity in multiple clinical studies. For example, in the LITESPARK-005 study, bezutivan was associated with a lower progression-free survival (PFS< /span>) was significantly prolonged, with an objective response rate (ORR) of 22% compared with 3.5% for everolimus. In addition, Bestifan also showed good efficacy in patients with VHL related renal cancer. Nearly half of the patients had tumors shrinking, and the median duration of response was not reached, showing a durable anti-tumor effect.

2. Safety and Tolerability

Bestifan has a good safety profile, and most adverse reactions are grade 1 or grade 2, such as anemia, fatigue, headache, hypoxia, etc. In the LITESPARK-005 study, only about 2% of patients discontinued treatment due to treatment-related adverse events, showing good tolerability. However, care needs to be taken to monitor for possible side effects such as anemia and hypoxia, especially in patients at high altitudes.

3. Patient feedback and quality of life

Patient feedback on besetifan has been generally positive. In a patient story sharing, patientGary ColeDescribes his positive changes following treatment with besetivan, emphasizing the improvement in quality of life the drug has produced. In addition, bezotivan showed longer progression-free survival and fewer treatment-related toxicities in the Q-TWiST analysis, further supporting its advantages in improving patients' quality of life.

4. Clinical application and prospects

Bestifan has been included in the National Comprehensive Cancer Network (NCCN) kidney cancer treatment guidelines as one of the first-choice treatments for patients with VHL related kidney cancer. Its application in patients with advanced or metastatic ccRCC is promising, especially for those patients who are resistant to traditional treatments. Besetivan provides a new treatment option. As more clinical data accumulates, bezotivan is expected to play a greater role in the treatment of renal cancer.

In summary, bezotivan, as a new type of HIF-2α inhibitor, has shown significant efficacy and good safety in the treatment of advanced or metastatic renal cancer. Positive feedback from patients and improvements in quality of life further support the value of its clinical application. With the deepening of research, bezutivan is expected to become an important drug in the treatment of kidney cancer.

Reference materials:https://www.drugs.com/